GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » OncoSec Medical Inc (FRA:ONMA) » Definitions » Net Current Asset Value

OncoSec Medical (FRA:ONMA) Net Current Asset Value : €-2.47 (As of Jan. 2023)


View and export this data going back to 2015. Start your Free Trial

What is OncoSec Medical Net Current Asset Value?

In calculating the Net Current Asset Value (NCAV), Benjamin Graham means a company's current assets (such as cash, marketable securities, and inventories) minus its total liabilities (including preferred stock, minority interest, and long-term debt).

OncoSec Medical's net current asset value per share for the quarter that ended in Jan. 2023 was €-2.47.

The historical rank and industry rank for OncoSec Medical's Net Current Asset Value or its related term are showing as below:

FRA:ONMA's Price-to-Net-Current-Asset-Value is not ranked *
in the Biotechnology industry.
Industry Median: 3.975
* Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.

OncoSec Medical Net Current Asset Value Historical Data

The historical data trend for OncoSec Medical's Net Current Asset Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

OncoSec Medical Net Current Asset Value Chart

OncoSec Medical Annual Data
Trend Jul13 Jul14 Jul15 Jul16 Jul17 Jul18 Jul19 Jul20 Jul21 Jul22
Net Current Asset Value
Get a 7-Day Free Trial Premium Member Only Premium Member Only 74.96 42.25 5.64 14.73 -0.29

OncoSec Medical Quarterly Data
Apr18 Jul18 Oct18 Jan19 Apr19 Jul19 Oct19 Jan20 Apr20 Jul20 Oct20 Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23
Net Current Asset Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 6.25 3.64 -0.29 -3.85 -2.47

Competitive Comparison of OncoSec Medical's Net Current Asset Value

For the Biotechnology subindustry, OncoSec Medical's Price-to-Net-Current-Asset-Value, along with its competitors' market caps and Price-to-Net-Current-Asset-Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


OncoSec Medical's Price-to-Net-Current-Asset-Value Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, OncoSec Medical's Price-to-Net-Current-Asset-Value distribution charts can be found below:

* The bar in red indicates where OncoSec Medical's Price-to-Net-Current-Asset-Value falls into.



OncoSec Medical Net Current Asset Value Calculation

OncoSec Medical's Net Current Asset Value (NCAV) per share for the fiscal year that ended in Jul. 2022 is calculated as

Net Current Asset Value Per Share(A: Jul. 2022 )
=(Total Current Assets-Total Liabilities-Minority Interest-Preferred Stock)/Shares Outstanding (EOP)
=(14.973-15.492-0-0)/1.79005
=-0.29

OncoSec Medical's Net Current Asset Value (NCAV) per share for the quarter that ended in Jan. 2023 is calculated as

Net Current Asset Value Per Share(Q: Jan. 2023 )
=(Total Current Assets-Total Liabilities-Minority Interest-Preferred Stock)/Shares Outstanding (EOP)
=(5.978-13.324-0-0)/2.9712
=-2.47

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


OncoSec Medical  (FRA:ONMA) Net Current Asset Value Explanation

Benjamin Graham first discussed net current asset value (NCAV) in the 1934 edition of "Security Analysis", which he coauthored with David Dodd. In the book, (net) current asset value is defined as:" current assets alone, minus all liabilities and claims ahead of the issue."

The common definition of NCAV is: NCAV = current assets – [total liabilities + minority interest + preferred stock]

Net current assets exclude not only the intangible assets but also the fixed and miscellaneous assets. In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. In "Security Analysis", preferred stock is dubbed "an imperfect creditorship position" that is best placed on the balance sheet alongside funded debt.

One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Graham’s strategy produced similar results.

Benjamin Graham looked for companies whose market values were less than two-thirds of their Net-Net Working Capital. They are collected under our Net-Net screener.


OncoSec Medical Net Current Asset Value Related Terms

Thank you for viewing the detailed overview of OncoSec Medical's Net Current Asset Value provided by GuruFocus.com. Please click on the following links to see related term pages.


OncoSec Medical (FRA:ONMA) Business Description

Traded in Other Exchanges
Address
24 North Main Street, Pennington, NJ, USA, 08534
OncoSec Medical Inc is a healthcare sector company. It is focused on designing, developing and commercializing gene therapies, therapeutics, and medical approaches to stimulate an anti-tumor immune response for the treatment of cancer. The company's lead product candidate, ImmunoPulse IL-12, consists of a plasmid construct encoding the proinflammatory cytokine, IL-12, which is delivered into the tumor through in vivo electroporation. In addition, it is pursuing ImmunoPulse IL-12 monotherapy in patients with triple-negative breast cancer.

OncoSec Medical (FRA:ONMA) Headlines

No Headlines